Sagent Pharmaceuticals (SGNT) Prices Up-Sized Offering at $16, High End of Range
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals (Nasdaq: SGNT) priced an up-sized initial public offering of 5,750,000 shares of common stock at a price to the public of $16.00 per share, the high end of the expected $14-$16 range.
Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering.
Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.
Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering.
Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FirstEnergy Corp. (FE) PT Raised to $35 at BofA Securities
- Jefferies Positive on Fair Isaac (FICO)
- Tencent (TCEHY) shares jump on 'Dungeon and Fighter' launch update
Create E-mail Alert Related Categories
Hot IPOs, IPOsRelated Entities
Morgan Stanley, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
